Karolinska Development's Modus Therapeutics Gets Approval For 2nd Part Of Phase 2 Study

RefinitivMoins d'1 minute de lecture

Karolinska Development AB KDEV:

REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY MODUS THERAPEUTICS RECEIVES APPROVAL FOR SECOND PART OF PHASE 2 STUDY IN CHRONIC KIDNEY DISEASE WITH ANEMIA

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles